In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Marketing Awards 2019 Winners Announced – GSK Crowned Company Of The Year, Pfizer’s Viagra Takes Best Brand

Executive Summary

GSK, Pfizer, HRA Pharma and Mentholatum all enjoyed a particularly fruitful evening at the OTC Marketing Awards 2019. J&J, P&G and RB were also among the winners at a celebration of the best and brightest in the UK consumer health market. 

You may also be interested in...



AESGP Annual Meeting, Day 2 (Part 4): OTC Advertising Isn’t Always About Brands

The fourth session of the AESGP 58th Annual Meeting in Madrid, Spain, focused on the use of advertising for responsible self-care. GSK Consumer Healthcare's general manager for Northern Europe, Jonathan Workman, argued that responsible advertising should start with “what people need, what people want.” Supporting Workman’s case for prevention-focused advertising, IPG Heath’s Zahid Siddique drew on his experience as both a marketing expert and pharmacist to show how consumer health campaigns can have positive impact on people’s lives.

HRA Pharma Launches Three-Hour Courier Service For EllaOne In The UK

HRA Pharma today launches an express courier service for emergency contraceptive EllaOne. Women in London can order EllaOne online and receive the product within three or 12 hours, women in the rest of the UK within 24 hours. 

Pfizer celebrates UK Viagra switch

Men in the UK will soon have OTC access to Pfizer’s blockbuster erectiledysfunction treatment Viagra after an application to switch the sildenafil-based product was given the green light.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel